Active substance
Cefpodoxime
- SFDA 6
- US FDA 12
- US price lines 4
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CEFODOX 100MG-5ML SUSPENSION | 20 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 53.00 | NCE · Prescription | Pharma International Co. | Valid |
| CEFODOX 200 MG FILM COATED TABLETS | 200 mg | Film-coated tablet · Oral use | 14 Blister | SAR 68.95 | Generic · Prescription | Pharma International Co. | Valid |
| Cefodox | 200 mg | Film-coated tablet · Oral use | 20 Blister | SAR 98.50 | Generic · Prescription | PHARMA INTERNATIONAL CO | Valid |
| ORELOX 100MG TABLETS | 100 mg | Tablet · Oral use | 10 Blister | SAR 30.80 | Generic · Prescription | SANOFI WINTHROP INDUSTRIE | Valid |
| EMDOX 100 mg/5 ml DS | 20 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 23.85 | Generic · Prescription | Med City Pharma | Withdrawn by MAH · Not Marketed |
| EMDOX 200 mg Film-coated Tablets | 200 mg | Film-coated tablet · Oral use | 10 Blister | SAR 55.45 | Generic · Prescription | Med City Pharma | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANTIMICROBIAL PROPHYLAXIS IN CANCER PATIENTS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; OSTEOMYELITIS; OTITIS MEDIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CEFPODOXIME PROXETIL | EQ 50MG BASE/5ML; EQ 100MG BASE/5ML | for suspension · oral | AUROBINDO PHARMA LTD | Prescription | 8 Jun 2007 |
| CEFPODOXIME PROXETIL | EQ 100MG BASE; EQ 200MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 11 Jun 2007 |
| CEFPODOXIME PROXETIL | EQ 100MG BASE; EQ 200MG BASE | tablet · oral | ANDA REPOSITORY | Prescription | 14 Nov 2007 |
| CEFPODOXIME PROXETIL | EQ 100MG BASE; EQ 200MG BASE | tablet · oral | SANDOZ | Prescription | 28 May 2008 |
| CEFPODOXIME PROXETIL | EQ 100MG BASE; EQ 200MG BASE | tablet · oral | ALKEM LABS LTD | Prescription | 18 May 2022 |
| VANTIN | EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 200MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | PFIZER | Discontinued | 7 Aug 1992 |
| VANTIN | EQ 50MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 100MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | for suspension · oral | PFIZER | Discontinued | 7 Aug 1992 |
| BANAN | EQ 100MG BASE; EQ 200MG BASE | tablet · oral | SANKYO | Discontinued | 7 Aug 1992 |
| BANAN | EQ 100MG BASE/5ML; EQ 50MG BASE/5ML | for suspension · oral | SANKYO | Discontinued | 7 Aug 1992 |
| CEFPODOXIME PROXETIL | EQ 50MG BASE/5ML; EQ 100MG BASE/5ML | for suspension · oral | SUN PHARM INDS LTD | Discontinued | 31 May 2002 |
| CEFPODOXIME PROXETIL | EQ 100MG BASE; EQ 200MG BASE | tablet · oral | SUN PHARM INDS LTD | Discontinued | 20 Aug 2003 |
| CEFPODOXIME PROXETIL | EQ 50MG BASE/5ML; EQ 100MG BASE/5ML | for suspension · oral | CHARTWELL RX | Discontinued | 14 Jan 2009 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CEFPODOXIME 100 MG TABLET | $1.0434 | per EA | 23 Sep 2026 |
| US NADAC | CEFPODOXIME 100 MG/5 ML SUSP | $1.04666 | per ML | 23 Sep 2026 |
| US NADAC | CEFPODOXIME 100 MG/5 ML SUSP | $0.98096 | per ML | 23 Sep 2026 |
| US NADAC | CEFPODOXIME 200 MG TABLET | $1.37245 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 11 Jun 2026 PRAC signal: Drug interaction between cefpodoxime and proton pump inhibitor (PPIs) resulting in a potentially reduced efficacy of cefpodoxime
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.